Lowell Weil, Jr., DPM, MBA, FACFAS
Past-President (2009-2010), International Society for Medical Shock Wave Treatment
"I was part of the investigational group that performed the study to get the Swiss DolorClast FDA approval. In my experience with three FDA studies on shock wave devices, the DolorClast had the highest success against placebo of any. Having recently finished my Presidency of the International Society for Medical Shock Wave Treatment, I have been very aware of the different studies from across the globe showing the beneficial effects that are created with the DolorClast. Personally, I have successfully treated hundreds of patients with the Swiss DolorClast including members of the Chicago White Sox, Chicago Bulls, Chicago Bears, and Chicago Fire as well as Olympic and College Athletes."
Larry DiDomenico DPM, ACFAS
"For both patient and physician, the EMS Swiss DolorClast has been a very user friendly procedure for the chronic condition of plantar fasciitis in my practice. In patients with failed non-surgical treatment, ESWT provides an excellent option to surgery. Not requiring anesthesia, the Swiss DolorClast office-based treatment is both very safe and effective."
John P. Furia MD
President, 2010 ATRAD World Congress
"I have been performing ESWT procedures since 2004 and have had the opportunity to use several shock wave generators. The Swiss DolorClast is by far the quickest, most versatile, user-friendly, well tolerated and effective ESWT device that I have ever encountered. Setting adjustment is intuitive, the targeting device is light, easy to aim, and greatly facilitates "clinical focusing" of the shock waves. Both portable and easy to maintain, the Swiss DolorClast has significantly improved the way I utilize shockwave therapy; I give the device my highest recommendations."
Carol C. Frey, MD
Fellowship Director, West Coast Sports Medicine Foundation, Assistant Clinical Professor of Orthopaedics , UCLA
"Published studies report that more than 2 million patients are treated for plantar fasciitis each year, accounting for approximately 11% to 15% of all foot-related encounters with physicians annually. Plantar fasciitis is a painful inflammatory process that when not treated can evolve into chronic degenerative changes in the fascia. Traditional treatment options, including conservative measures and medication, have shown success rates from 44% to 82%. Surgical intervention with open or endoscopic release of the plantar fascia has unpredictable results, substantial risks and recovery is usually very slow - 1 year. Researchers have been building a strong body of published clinical evidence for ESWT. ESWT has been shown to be safe and effective in several prospective randomized studies including studies by Gerdesmeyer. In cases of failed nonsurgical treatment, ESWT represents an excellent option to surgery and radial ESWT may be a better option than focused ESWT, as anesthesia is not required."
Howard A. Penn DPM, FACFS
"Radial shockwave therapy with the EMS Swiss DolorClast has been a tremendous asset to my practice since 2007. The fact that this office-based, 10 minute procedure is non-invasive, requires no anesthesia, and has no documented complications makes this a very attractive procedure to my patients with chronic plantar fasciitis. The high success rates achieved with this technology has almost virtually minimized the need for surgery. I highly recommend the Swiss DolorClast system to any practitioner dealing with chronic heel pain."
Eric M. Bluman, MD, PhD
Orthopaedic Foot and Ankle Surgeon
"EMS/Swiss DolorClast Radial Shockwave Therapy has revolutionized my practice. Since my initial use in 2007, EMS radial shockwave virtually eliminated my surgical treatment of refractory plantar fasciitis. My patients are much more comfortable knowing that there is a non-operative office-based treatment available should physical therapy and other methods fail to relieve their plantar fasciitis pain."